Evidence map›Paper›PMID 27365493›Full record

ArticleHeart (British Cardiac Society)2016

Marginal role for 53 common genetic variants in cardiovascular disease prediction.

Richard W Morris, Jackie A Cooper, Tina Shah, Andrew Wong, Fotios Drenos, Jorgen Engmann, Stela McLachlan, Barbara Jefferis, Caroline Dale, Rebecca Hardy and 13 more

Abstract read
In one paragraph

Article in Heart (British Cardiac Society), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Preventive Cardiology and Risk Assessment: Beyond LDL.Current atherosclerosis reports · 2020
    Review
  7. Article
  8. Article
  9. Promises, promises, and precision medicine.The Journal of clinical investigation · 2019
    Review
  10. Article
  11. Article
  12. Cardiovascular Risk Stratification: From Phenotype to Genotype?Arquivos brasileiros de cardiologia · 2018
    Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Richard W MorrisSchool of Social & Community Medicine, University of Bristol, Bristol, UK Department of Primary Care & Population Health, University College London, London, UK.
Jackie A CooperCentre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK.
Tina ShahInstitute of Cardiovascular Science and Farr Institute, University College London, London, UK.
Andrew WongMRC Unit for Lifelong Health and Ageing at UCL, London, UK.
Fotios DrenosInstitute of Cardiovascular Science and Farr Institute, University College London, London, UK MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, UK.
Jorgen EngmannInstitute of Cardiovascular Science and Farr Institute, University College London, London, UK.
Stela McLachlanCentre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
Barbara JefferisDepartment of Primary Care & Population Health, University College London, London, UK.
Caroline DaleDepartment of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Rebecca HardyMRC Unit for Lifelong Health and Ageing at UCL, London, UK.
Diana KuhMRC Unit for Lifelong Health and Ageing at UCL, London, UK.
Yoav Ben-ShlomoSchool of Social & Community Medicine, University of Bristol, Bristol, UK.
S Goya WannametheeDepartment of Primary Care & Population Health, University College London, London, UK.
Peter H WhincupDivision of Population Health Sciences and Education, St George's, University of London, London, UK.
Juan-Pablo CasasCentre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK.
Mika KivimakiDepartment of Epidemiology & Public Health, UCL Institute of Epidemiology & Health Care, University College London, London, UK.
Meena KumariDepartment of Epidemiology & Public Health, UCL Institute of Epidemiology & Health Care, University College London, London, UK Institute for Social and Economic Research, University of Essex, Colchester, UK.
Philippa J TalmudCentre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK.
Jacqueline F PriceCentre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
Frank DudbridgeDepartment of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Aroon D HingoraniInstitute of Cardiovascular Science and Farr Institute, University College London, London, UK.
Steve E HumphriesCentre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK.
UCLEB Consortium

Funding

Socio-economic status and heterogeneity in agingR01AG013196 · NIA · UNIVERSITY OF LONDON INST OF NEUROLOGY · PI MARMOT, MICHAEL G, SINGH-MANOUX, ARCHANA · 1996 to 2013
$3.5M
Socioeconomic gradient in CHD in early old ageR01HL036310 · NHLBI · UNIVERSITY OF LONDON · PI KIVIMAKI, MIKA J, MARMOT, MICHAEL G · 1986 to 2012
$3.1M
British Heart Foundation PG/13/66/30442British Heart Foundation RG/08/008/25291British Heart Foundation RG/08/013/25942British Heart Foundation RG/10/12/28456British Heart Foundation RG/13/16/30528British Heart Foundation RG/13/2/30098Medical Research Council MC_UU_12013/5Medical Research Council MC_UU_12019/1Medical Research Council MR/K006215/1Medical Research Council MR/K006584/1Medical Research Council MR/K013351/1Medical Research Council MR/M026175/1NHLBI NIH HHS R01 HL036310NIA NIH HHS R01 AG013196
6 · The paper itself

Abstract

objectiveWe investigated discrimination and calibration of cardiovascular disease (CVD) risk scores when genotypic was added to phenotypic information. The potential of genetic information for those at intermediate risk by a phenotype-based risk score was assessed.

methodsData were from seven prospective studies including 11 851 individuals initially free of CVD or diabetes, with 1444 incident CVD events over 10 years' follow-up. We calculated a score from 53 CVD-related single nucleotide polymorphisms and an established CVD risk equation 'QRISK-2' comprising phenotypic measures. The area under the receiver operating characteristic curve (AUROC), detection rate for given false-positive rate (FPR) and net reclassification improvement (NRI) index were estimated for gene scores alone and in addition to the QRISK-2 CVD risk score. We also evaluated use of genetic information only for those at intermediate risk according to QRISK-2.

resultsThe AUROC was 0.635 for QRISK-2 alone and 0.623 with addition of the gene score. The detection rate for 5% FPR improved from 11.9% to 12.0% when the gene score was added. For a 10-year CVD risk cut-off point of 10%, the NRI was 0.25% when the gene score was added to QRISK-2. Applying the genetic risk score only to those with QRISK-2 risk of 10%-<20% and prescribing statins where risk exceeded 20% suggested that genetic information could prevent one additional event for every 462 people screened.

conclusionThe gene score produced minimal incremental population-wide utility over phenotypic risk prediction of CVD. Tailored prediction using genetic information for those at intermediate risk may have clinical utility.

Indexed as

Gene Expression ProfilingPolymorphism, Single NucleotideAdultArea Under CurveCardiovascular DiseasesFalse Positive ReactionsFemaleGenetic Association StudiesGenetic MarkersGenetic Predisposition to DiseaseHumansIncidenceMaleMiddle AgedPhenotypePredictive Value of TestsGenetic Markers

Identifiers

PMID27365493
PMCPMC5099215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.